ALK and cancer: Clinically actionable targets and active inhibitors against targets in cancer cells have been demonstrated2, and small-molecule inhibitors have been approved by the US Food and Drug Administration (FDA) for use against tumor cells with addicted oncogenes, including HER2, ALK, BRAF, and EGFR3.